Philosys Healthcare Completes Second Supply of Specimen Collection Kits Worth 8.8 Billion KRW to the US and UAE

[Asia Economy Reporter Jang Hyowon] Philosis Healthcare (CEO Choi Inhwan) announced on the 22nd that it has completed the second delivery of specimen collection kits worth approximately 8 million USD (about 8.8 billion KRW) supplied to the United States and the United Arab Emirates (UAE).

Philosis Healthcare signed an export contract for specimen collection kits worth a total of 48 million USD (about 52.9 billion KRW) to the US and UAE through H&Dream and CareCamp on January 26. The first delivery worth 2.4 million USD (about 2.7 billion KRW) was made last month, and the second supply has also been sequentially completed, with continuous shipments scheduled until the end of August.

As the COVID-19 situation continues, demand for specimen collection kits along with diagnostic kits remains strong. Philosis Healthcare’s specimen collection kits have improved materials and structure to easily release viruses absorbed in a special solution along with medical swabs that effectively absorb viruses. The company is currently filing patents domestically and has obtained approval from the U.S. Food and Drug Administration (FDA), actively targeting the global market.

A company representative stated, “Specimen collection kits are currently being supplied stably and will be fully delivered by the end of August. Additional deliveries to countries other than the US and UAE are currently under discussion, and we are making efforts to diversify export countries along with the US and UAE.”

Meanwhile, Philosis Healthcare achieved an earnings surprise last year, escaping from the management watchlist, and is accelerating post-COVID businesses such as smart care zones alongside its COVID-19 prevention business.

This content was produced with the assistance of AI translation services.